Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytyc pays $160million for breast radiation therapy firm

This article was originally published in Clinica

Executive Summary

Cytyc has agreed to pay $160m in cash for Proxima Therapeutics, a private company with an FDA-cleared post-lumpectomy targeted radiation therapy system for early-stage breast cancer. Proxima also sells a similar system to treat resected brain tumours, which Cytyc hopes to divest because it does not fit into its focus on women's health. Both products involve the use of a balloon catheter to deliver a radiation source directly to the cavity left following the removal of the tumour.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts